Elite Pharmaceuticals, Inc. Stock price

Equities

ELTP

US28659T2006

Pharmaceuticals

Market Closed - OTC Markets 03:59:51 2024-03-28 pm EDT 5-day change 1st Jan Change
0.1543 USD +0.88% Intraday chart for Elite Pharmaceuticals, Inc. +3.56% +10.21%
Sales 2022 32.26M Sales 2023 34.16M Capitalization 29.4M
Net income 2022 8M Net income 2023 3M EV / Sales 2022 0.92 x
Net cash position 2022 5.75M Net cash position 2023 3.94M EV / Sales 2023 0.75 x
P/E ratio 2022
4.73 x
P/E ratio 2023
9.34 x
Employees 53
Yield 2022 *
-
Yield 2023
-
Free-Float 82.63%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System Stimulant CI
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR to Marketing Partner Prasco, LLC CI
Transcript : Elite Pharmaceuticals, Inc., Q2 2024 Earnings Call, Nov 15, 2023
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic Product CI
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer CI
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study CI
Transcript : Elite Pharmaceuticals, Inc., Q1 2024 Earnings Call, Aug 15, 2023
Elite Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Transcript : Elite Pharmaceuticals, Inc., 2023 Earnings Call, Jun 30, 2023
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Elite Pharmaceuticals, Inc Appoints Mark Pellegrino as its Chief Financial Officer CI
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product CI
More news
1 day+0.88%
1 week+3.56%
Current month-6.43%
1 month-2.65%
3 months+9.59%
6 months+68.63%
Current year+10.21%
More quotes
1 week
0.14
Extreme 0.137
0.16
1 month
0.13
Extreme 0.129
0.17
Current year
0.13
Extreme 0.129
0.21
1 year
0.03
Extreme 0.028
0.21
3 years
0.02
Extreme 0.023
0.21
5 years
0.02
Extreme 0.023
0.21
10 years
0.02
Extreme 0.023
0.51
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 13-07-31
Director of Finance/CFO 59 09-06-30
President 69 02-10-31
Members of the board TitleAgeSince
Director/Board Member 68 09-10-22
Director/Board Member 93 05-03-31
Director/Board Member 76 16-04-27
More insiders
Date Price Change Volume
24-03-28 0.1543 +0.88% 500 606
24-03-27 0.153 +0.43% 170,933
24-03-26 0.1524 +0.36% 352,404
24-03-25 0.1518 +0.40% 1,698,465
24-03-22 0.1512 -1.08% 209,759

Delayed Quote OTC Markets, March 28, 2024 at 03:59 pm EDT

More quotes
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Company’s products include Phentermine HCl 37.5mg tablets, Phendimetrazine Tartrate 35mg tablets, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock Elite Pharmaceuticals, Inc. - OTC Markets